search
Back to results

A Noval Tau Tracer in Young Onset Dementia

Primary Purpose

Alzheimer's Disease, Vascular Dementia, Dementia

Status
Not yet recruiting
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
18F-PM-PBB3
Sponsored by
Chang Gung Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Alzheimer's Disease

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Subjects

Very mild to moderate stage YOD inclusion criteria:

Age between 20-75 years old.

YOD is defined by the dementia onset before age 65 years old. The dementia syndrome is based on the NIA-AA criteria of all-cause of dementia . Briefly it required:

  1. Interfere with the ability to function at work or at usual activities.
  2. Represent a decline from previous levels of functioning and performing.
  3. Cognitive impairment is detected and diagnosed through a combination of a). history-taking form the patient and a knowledgeable informant b). an objective cognitive assessment, either a 'bedside' mental status examination or neuropsychological testing.
  4. The cognitive or behavioral impairment involves a minimum of two of the below domains: impaired ability to acquire and remember new information, impaired reasoning and handling of complex tasks poor judgment, impaired visuospatial abilities, impaired language functions, changes in personality, behavior or comportment symptoms.

The severity of dementia is limited from very mild to moderate stage in current project. The definition of very mild to moderate stage of dementia is based on the clinical dementia rating scale (CDR) from 0.5-2 YOD_2019 3 Exclusion Criteria

  1. Implantation of metal devices including cardiac pacemaker, intravascular metal devices.
  2. Major systemic diseases including coronary arterial disease, heart failure, uremia, hepatic failure, prominent strokes, acute myocardial infarction, poorly controlled diabetes, previous severe head injury, intracranial operation, hypoxia, sepsis or severe infectious diseases.
  3. Major psychiatric disorders, drug or alcohol abuse and major depression
  4. Pregnant women or breast- feeding women.
  5. Patients in whom MRI was contraindicated or patient had claustrophobia.
  6. History of severe allergic or anaphylactic reactions particularly to the tested drugs.
  7. History of positive test for human immunodeficiency virus (HIV).
  8. Indication of impaired liver function as shown by an abnormal liver function profile at screening (eg. repeated values of aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≧ 3X the upper limit of normal values).

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    The relationship between image and AD disease

    Arm Description

    To evaluate the relationship between F-18-PMPBB3 PET image uptake pattern and AD disease classifications.

    Outcomes

    Primary Outcome Measures

    understand the proportion of subtype in YOD
    investigator would be able to understand the proportion of subtype in YOD
    understand the mean tau deposition in different region of interest from subtype of YOD
    investigator will perform image analysis to understand tau deposition in different subtype of YOD based on 18F-PM-PBB3 tau tracer image. The mean intensity from selected region of interest will be recorded for different group comparison.
    understand the mean tau intensity in different region of interest and find correlation with cognition
    investigator will perform association study to explore clinical measurements such as cognition and demographic data associate with tau intensity from different region of interest

    Secondary Outcome Measures

    Full Information

    First Posted
    January 21, 2020
    Last Updated
    January 28, 2020
    Sponsor
    Chang Gung Memorial Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04248270
    Brief Title
    A Noval Tau Tracer in Young Onset Dementia
    Official Title
    A Noval Tau Tracer ([18F]PM-PBB3) in Young Onset Dementia: Clinical and Neuroimaging Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2020
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    February 20, 2020 (Anticipated)
    Primary Completion Date
    August 17, 2023 (Anticipated)
    Study Completion Date
    November 30, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Chang Gung Memorial Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    Dementia is a clinical syndrome which characterized by progressive cognitive impairment, behavior disturbance and dysfunction of daily activity. In aging population, Alzheimer's dementia (AD) is the most common late onset dementia which occupied about 50-75%, the vascular dementia, frontotemporal lobardegeneration (FTLD) and corticobasal syndrome is followed. On the other hand, the young onset dementia (YOD), which represents the onset of dementia before65 years old, is only about 1/10 to 1/100 proportion of late onset dementia. The YOD is different from late onset dementia in the proportion of degenerative subtype (e.g. the FTLD is more frequent than AD). Besides, frequent atypical presentation of clinical syndrome in the YOD which characterize the different variant of AD made the early accurate diagnosis of AD is more difficult. Currently, there is no available data to describe the proportion of subtype in YOD in Taiwan. In AD dementia, two important biomarkers are amylod plaque made by ß-amyloid protein and neurofibrillary tangle made by phosphorylation tau protein. In the past, they only can be seen under the microscope findings at autopsy study. Recently, the new amyloid tracer and tau tracer had been developed and could evaluate the deposition of amyloid and tau protein in human brain. These progresses had substantially improved the accurate diagnosis of degenerative dementia. A noval tau tracer [ 18F]PM-PBB3, which had substantially improved the off-target binding and more clear background in human brain than previous tau tracer. In current project, investigator will aim to consecutive collect 50 YOD due to the neurodegeneration in 3 years using the NIA-AA research framework system(ATN system) to achieve accurate diagnosis of the dementia subtype by the detail clinical neurology study, neuropsychological examination, amyloid positron emission tomography (PET) and tau PET study. In the first year, investigator will perform feasibility study to explore the topographical tau distribution in different subtype of YOD. In the next 2 years, investigator will perform a large scale study in a group of YOD to understand the amyloid and tau deposition and their association with clinical parameters. From current project, investigator could understand the tau deposition in different YOD subtype. Investigator also could understand the correlation between clinical phenotype and molecular pathology. Investigator will use a mathematic model to construct the model of diffusion kurtosis imaging from brain magnetic resonance imaging (MRI) and relate the white matter integrity with amyloid and tau PET imaging.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Alzheimer's Disease, Vascular Dementia, Dementia

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    100 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    The relationship between image and AD disease
    Arm Type
    Other
    Arm Description
    To evaluate the relationship between F-18-PMPBB3 PET image uptake pattern and AD disease classifications.
    Intervention Type
    Drug
    Intervention Name(s)
    18F-PM-PBB3
    Intervention Description
    All scans will be acquired in pairs of 18F-florbetapir(18F-AV45) and/or18F-PM-PBB3 PET scans (if patient select), performed on separate days, and at least 2 days apart, with either scan performed first. The 18F-florbetapir and 18F-PM-PBB3 protocol will entail the inon of 5±2mCi of tracer followed by an uptake phase of 50 min during which time the state of the subject is not important. After 40 minutes, subjects will be positioned and 4 x 5 min frames of emission data will be collected right at 50 min after tracer injection. PET/MRI scans will precede this acquisition with a MRI scan for attenuation correction; PET-only scanners will perform a transmission scan following the emission scan.
    Primary Outcome Measure Information:
    Title
    understand the proportion of subtype in YOD
    Description
    investigator would be able to understand the proportion of subtype in YOD
    Time Frame
    3 years
    Title
    understand the mean tau deposition in different region of interest from subtype of YOD
    Description
    investigator will perform image analysis to understand tau deposition in different subtype of YOD based on 18F-PM-PBB3 tau tracer image. The mean intensity from selected region of interest will be recorded for different group comparison.
    Time Frame
    3 years
    Title
    understand the mean tau intensity in different region of interest and find correlation with cognition
    Description
    investigator will perform association study to explore clinical measurements such as cognition and demographic data associate with tau intensity from different region of interest
    Time Frame
    3 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria Subjects Very mild to moderate stage YOD inclusion criteria: Age between 20-75 years old. YOD is defined by the dementia onset before age 65 years old. The dementia syndrome is based on the NIA-AA criteria of all-cause of dementia . Briefly it required: Interfere with the ability to function at work or at usual activities. Represent a decline from previous levels of functioning and performing. Cognitive impairment is detected and diagnosed through a combination of a). history-taking form the patient and a knowledgeable informant b). an objective cognitive assessment, either a 'bedside' mental status examination or neuropsychological testing. The cognitive or behavioral impairment involves a minimum of two of the below domains: impaired ability to acquire and remember new information, impaired reasoning and handling of complex tasks poor judgment, impaired visuospatial abilities, impaired language functions, changes in personality, behavior or comportment symptoms. The severity of dementia is limited from very mild to moderate stage in current project. The definition of very mild to moderate stage of dementia is based on the clinical dementia rating scale (CDR) from 0.5-2 YOD_2019 3 Exclusion Criteria Implantation of metal devices including cardiac pacemaker, intravascular metal devices. Major systemic diseases including coronary arterial disease, heart failure, uremia, hepatic failure, prominent strokes, acute myocardial infarction, poorly controlled diabetes, previous severe head injury, intracranial operation, hypoxia, sepsis or severe infectious diseases. Major psychiatric disorders, drug or alcohol abuse and major depression Pregnant women or breast- feeding women. Patients in whom MRI was contraindicated or patient had claustrophobia. History of severe allergic or anaphylactic reactions particularly to the tested drugs. History of positive test for human immunodeficiency virus (HIV). Indication of impaired liver function as shown by an abnormal liver function profile at screening (eg. repeated values of aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≧ 3X the upper limit of normal values).

    12. IPD Sharing Statement

    Learn more about this trial

    A Noval Tau Tracer in Young Onset Dementia

    We'll reach out to this number within 24 hrs